REGN5459 Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
REGN5459 appears safe and can produce durable responses in patients with relapsed or refractory multiple myeloma, a phase 1/2 study suggests.
Diagnosis & Disease Information
Dabrafenib-Trametinib Combo Proves Active in Rare BRAF-Mutated Cancers
Combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the BRAF V600E mutation.
Phase 2 Studies Investigate Combination Therapies, BCMA in Patients With Relapsed/Refractory Multiple Myeloma
Researchers are conducting phase 2 trials to assess various combination therapies, including BCMA, in patents with relapsed/refractory multiple myeloma.
Minimal Residual Disease Negativity Predicts Time to Next Treatment in Multiple Myeloma
Patients with sustained minimal residual disease negativity had longer time to next treatment, regardless of baseline risk characteristics.
Adding Metronomic Cyclophosphamide to Ixazomib, Cyclophosphamide, and Dexamethasone Not Recommended for Multiple Myeloma
Researchers sought to determine whether patients with newly diagnosed MM would benefit from adding metronomic cyclophosphamide to an all-oral ixazomib, cyclophosphamide, and dexamethasone.
Use of Frailty Scale Based on Patient‑Reported Outcomes Feasible in Multiple Myeloma
Researchers sought to determine whether using a frailty scale constructed from existing patient-reported outcomes would be feasible in clinical trials for multiple myeloma.
Processed Red Meat Intake Linked to Increased Incidence of Blood Cancers
No associations seen for intake of other foods and fatty acids with acute myeloid leukemia/myelodysplastic syndrome.
Symptom Burden Level in Multiple Myeloma Defined by Clinical, Other Characteristics
Researchers conducted a cross-sectional study to identify patterns of demographic and clinical characteristics that corresponded to level of symptom burden in patients with multiple myeloma.
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Health-Related QOL Not Addressed in Standard Care of Patients With Multiple Myeloma
Researchers sought to determine which QOL tools are being used as part of routine care for patients with multiple myeloma.
- Loading...
Loading...
Next post in Myeloma
Loading... 
Loading...